Zealand Pharma

finance numbers tape money
Biotech

Roche pays Zealand $1.6B to codevelop amylin obesity asset

The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to codevelop and co-commercialize Zealand's long-acting amylin analog.
Nick Paul Taylor Mar 12, 2025 5:23am
parachute snow mountains

Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders

Jan 10, 2025 8:30am
Image of a neon sign with the word no lit up next to an unlit yes

FDA hits Zealand Pharma's Gattex challenger with CRL

Dec 19, 2024 4:22pm
Stock exchange concept

Ironwood makes further bid for $1B GI drug with subgroup data

Oct 28, 2024 12:33pm
obesity overweight weight loss weigh

Zealand Pharma’s GLP-1/GLP-2 agonist tied to 8.3% weight loss

Sep 10, 2024 10:45am
parachute sunset paragliding chutes

Takeda taps new head of US oncology business—Chutes & Ladders

Aug 2, 2024 8:30am